Lakefront Biotherapeutics/€LKFT

1D1W1MYTD1Y5YMAX

About Lakefront Biotherapeutics

Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.
Ticker
€LKFT
Sector
Health
Primary listing
AEX
Employees
196
Headquarters
Mechelen, Belgium
Website
lakefrontbio.com

LKFT Metrics

BasicAdvanced
€1.7B
2.86
€9.05
0.12
-

What the Analysts think about LKFT

Analyst ratings (Buy, Hold, Sell) for Lakefront Biotherapeutics stock.
Analyst projections of the future price of Lakefront Biotherapeutics stock.

Bulls say / Bears say

Lakefront’s lead asset, gamgertamig, is in Phase 1b studies for autoimmune diseases and has FDA Fast Track and Orphan Drug designations for AIHA and ITP. Registrational studies could start as early as 2027, with Gilead supporting development. (Lakefront Biotherapeutics, BioPharmaWatch)
The revised Gilead agreement gives Lakefront up to $500 million to pursue deals outside the existing partnership, including up to $150 million for potential share repurchases. Management also expects to retain roughly €2 billion of cash and investments at the end of 2026, leaving substantial funding for further opportunities. (Lakefront Biotherapeutics, GlobeNewswire)
A former Galapagos asset, COL-5671, attracted a $125 million Series A financing for Coultreon Biopharma, which plans Phase 2 testing in psoriasis and ulcerative colitis. External funding could help develop this programme without Lakefront bearing the full cost. (BioPharma Dive)
The Phase 2 GALACELA study of GLPG3667 in systemic lupus erythematosus missed both its primary endpoint at 32 weeks and the comparable secondary endpoint at 48 weeks. Lakefront is now considering strategic options for the programme, weakening the depth of its pipeline. (Ideal Investor)
Gamgertamig remains an early-stage Phase 1b programme, with registrational trials only targeted as early as 2027. Durable efficacy, safety and competitive differentiation are still unproven, so the investment case depends heavily on future clinical results. (Lakefront Biotherapeutics, Seeking Alpha)
The transformation is consuming cash before meaningful product revenue arrives: 2026 guidance includes €775–790 million of Ouro-related spending and €125–175 million of cell-therapy wind-down costs. First-half cash and investments fell to €2.24 billion, while revenue fell 96% year on year to €4.5 million. (Lakefront Biotherapeutics, Ideal Investor)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.

LKFT Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

LKFT Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing LKFT

AllUSDEURGBP
Funds
Fund name
Fund size
€LKFT weighting
iShares Healthcare Innovation$HEAL
$1.4B0.11%
iShares Healthcare Innovation€2B78
€1.2B0.11%
iShares Healthcare Innovation£DRDR
£1B0.11%
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.06%
Xtrackers MSCI Europe Small Cap£XXSC
£2.8B0.06%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.